Sino Biopharmaceutical
TOPIC
 / company

Sino Biopharmaceutical

Sino Biopharmaceutical
Sino Biopharmaceutical
Sino Biopharmaceutical develops, manufactures and markets pharmaceuticals, biopharmaceuticals and Chinese medicines. It offers products to treat conditions ranging from hepatitis to respiratory and digestive diseases. It is a subsidiary of Thailand's Charoen Pokphand Group.
Chairman / President
Theresa Tse
CEO / Managing Director
Tse, Eric S Y
CFO / Finance Director
Li Chunling
Industry
Pharmaceuticals
Website
sinobiopharm.com
Headquarters address
Unit 09, 41/F, Office Tower, Convention Plaza, 1 Harbour Road, Wanchai, Hong Kong
Stock Code
SEHK:1177
Year founded
2000
People walk past Exchange Square in Central, home of Hong Kong’s bourse operator, on March 28, 2025. Photo: Matthew Miller
Hong Kong stock market

Hong Kong stocks edge higher on last full trading day of year

Hang Seng Index edges higher as Chinese yuan surpasses 7 against US dollar for first time since May 2023.

Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

10
Hong Kong stock market

Hong Kong stocks slip from 4-year high amid fears of US sanctions on drug makers

The Trump administration has been discussing severe restrictions on medicines from China, according to The New York Times.

Hong Kong stocks fell on Thursday. Photo: EPA
Hong Kong stock market

Hong Kong stocks rise on China policy hopes after soft economic data

China’s industrial output and fixed-asset investment fell short in May, and the downturn in the property market deepened.

Hong Kong stock market

Hong Kong stocks fall on rising geopolitical tensions

Israel launches air strikes targeting both nuclear and military sites and officials leading Iran’s nuclear programme.

Advertisement
Advertisement
Advertisement
Hong Kong stock market

Hong Kong stocks fall on US trade threats and interest rate uncertainty

US President Donald Trump says he will unveil unilateral tariff rates within two weeks.

People walk through Exchange Square in Central. Photo: EPA-EFE
Science

US approves China-invented painkiller that could reduce fentanyl overdoses

Qamzova is a non-steroidal anti-inflammatory that provides 24-hour pain relief in a single shot, reducing post-surgery opioid reliance.

videocam
23
Hong Kong stock market

China’s first rate cut in 7 months drives Hong Kong stocks to 2-month high

Lower borrowing costs will be a major driver for stocks, Guotai Haitong Securities analysts Fang Yi says.

Science

Drug trial offers hope for patients with hard-to-treat lung cancer in China, US

New medication appears to be safer and more effective than standard therapy, according to trial led by Chinese and US scientists.

videocam
7
Lung cancer is the most prevalent type of the disease worldwide, with an estimated 2.5 million new cases globally last year. Photo: PR NEWSWIRE
Coronavirus pandemic

Sino Biopharm invests US$515 million in Sinovac’s Covid-19 vaccine unit

Beijing-based generic drug maker buys 15 per cent stake in Sinovac Life Sciences, a unit of Nasdaq-listed pharmaceutical firm Sinovac Biotech.

videocam
Sinovac Biotech’s CoronaVac Covid-19 vaccine candidate has been undergoing phase three trials in many countries, including Brazil and Turkey. Photo: AFP
Stocks

Stocks Blog: China stocks gain ahead of global financial leaders' teleconference call on coronavirus

Reuters reports draft statement of G7 leaders does not include specific, coordinated steps. That led to a pullback in Asia markets. In Hong Kong, Tencent, Ping An Good Doctor, China Tobacco International gained. In China, Kweichow Moutai advanced. 

Hang Seng Index

Sino Biopharmaceutical added to Hong Kong index amid Beijing biotech push

An index that tracks shares of mainland Chinese companies on the Hong Kong stock exchange will admit a pharmaceutical stock and a utility. The companies replace a railway company and a building materials producer, partly reflecting the changing profile of China’s economy.

Wealth management

Eric Tse, Rihanna’s selfie mate, is instant tycoon on US$3.8 billion gift

The share transfer is the latest in the tsunami of Asian wealth that’s being passed down to the next generation. In 2018, four Chinese tycoons tipped more than US$17 billion into family trusts, while many of Hong Kong’s biggest developers are going through succession planning.

A self picture of Eric Tse with Rihanna. Photo: Instagram @erictse0816
Advertisement
Advertisement
Advertisement